



Renal Sympathetic Denervation for, Any updates after SIMPLICITY III?

Mohamed Atef Hamza, MD
Associate professor of cardiology
Ain shams university

Hypertension


- Hazards of hypertension
- Difficult to treat due to multiple mechanisms
- Secondary HTN

Goal ?



How to reach ?







Evidence

1 Month	3 Months	6 Months	12 Months	18 Months	24 Months	36 Months
Symplicity HTN-1 [n = 153]						
-19/-9 (n = 143)	-21/-10 (n = 148)	-22/-10 (n = 144)	-27/-14 (n = 132)	NR	-29/-14 (n = 105)	-31/-16 (n = 34)
Symplicity HTN-2 [n = 106]						
-20/-7 (n = 49)	-24/-8 (n = 49)	-32/-12 (n = 49)	-28/-10 (n = 47)	-32/-12 (n = 43)	-29/-10 (n = 40)	NR

Symplicity HTN-1 (2009)



Symlicity HTN-2 (2010)



2014

- Symlicity HTN-3
- Symlicity HTN-3 (12 month follow up)
- Global Symlicity Registry


Symplicity HTN-3 (2014)



Symplicity HTN-3 (2014)

- SYMPLICITY HTN-3 is the first prospective, multi-center, randomized, blinded trial.
- 535 patients underwent randomization.
- Renal denervation vs. sham procedure.

Symplicity HTN-3 (2014)



Symplicity HTN-3 (2014)

After 3 years
of success






- No significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after RDN compared with control.

Failed

2014

- Symplicity HTN-3
- Symplicity HTN-3 (12 month follow up)
- Global Symplicity Registry






2014

- Symplicity HTN-3
- Symplicity HTN-3 (12 month follow up)
- Global Symplicity Registry

Background

- The Global Symplicity Registry is a multi-center, randomized, controlled, procedural and medical therapy trial in a population of patients with resistant hypertension.
- The registry will evaluate the effect of RDN on the following outcomes:
 - Blood pressure
 - Conditions
 - Differences
- Follow-up results in the first 2,700 enrolled patients for **12 months** are available.



Procedural Details


	N=1000
Number of renal arteries	2.2 ± 0.5
Treatment time, min	50.4 ± 21.6
Number of ablations	13.5 ± 4.1
Number of 120 sec ablations	11.4 ± 3.5
Contrast volume used, cc (IQR*)	127.8 ± 81.1 (70, 160)



*25-75% intra-quartile range




Operator Experience in GSR

- 189 operators did 1,000 procedures







2014

Journal Of Interventional Cardiology

An International Forum for Global Cardiovascular Therapies

Original Investigation

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: Egyptian Experience

MOHAMED HAMZA MD* and HAZEM KHAMIS MD

Article first published online: 19 JUL 2014
DOI: 10.1111/joic.12135
© 2014, Wiley Periodicals, Inc.


Issue

Journal of Interventional Cardiology
Volume 27, Issue 4, pages 423–427, August 2014

What's new ?

- 1. New catheter system
- 2. Anatomical


Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter Can Access Vessels 3-8 mm



- Curved four-quadrant design
- 22 catheter ports
- 22 gold electrode contacts
- 220V over the wire radiofrequency delivery
- Advanced bifurcated energy delivery
- Minimal trauma (length: 0.8 cm)
- With unique handle to control energy delivery

What's new ?

Our View of Renal Nerve Distribution Has Changed




Spyral-HTN




Spyral-HTN



SPYRAL HTN-OFF MED Study



Spyral-HTN



THM

- Renal denervation is still under investigation with more understanding of the technique and improvement of the learning curve
- Better renal anatomy understanding.
- More ablations needed including renal artery and branches.
- New catheter system
- SPYRAL-HTN trial.

THANK YOU